A molecular-spin qubit includes a molecular color center having a ground state and an excited state. The ground state has non-zero spin with at least first and second sublevels. The molecular-spin qubit also includes a host matrix that is non-isostructural with the molecular color center. The molecular color center is diluted in the host matrix. An optical transition between the ground and excited states lies in the optical region of the electromagnetic spectrum. A spin transition between the first and second sublevels lies in the microwave or millimeter-wave regions of the electromagnetic spectrum. Each of the first and second sublevels is first-order insensitive to magnetic fields near zero magnetic. The molecular color center and host matrix may each be formed from strong-field ligands bound to a metal-atom center. One example of the molecular-spin qubit is Cr(IV)(o-toyl)4 diluted in a host matrix of Sn(IV)(4-fluoro-2-methylphenyl)4.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
Stretchable light-emitting polymers are provided. Stretchable organic light-emitting diodes including the stretchable light-emitting polymers are further provided.
H10K 50/11 - OLED ou diodes électroluminescentes polymères [PLED] caractérisées par les couches électroluminescentes [EL]
C08F 26/06 - Homopolymères ou copolymères de composés contenant un ou plusieurs radicaux aliphatiques non saturés, chaque radical ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par une liaison simple ou double à l'azote ou par un hétérocycle contenant de l'azote par un hétérocycle contenant de l'azote
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
Provided herein are pharmaceutical compositions and dietary supplements comprising vanadyl sulfate (VS) and method of use thereof for the induction of cell death in senescent cells. In particular. VS compositions find use in clearance of age-related and/or therapy-induced senescent cells and reduction/elimination of senescence associated secretory phenotype (SASP)-induced inflammatory environments in subjects. and therefore in the treatment/prevention of age-related conditions and/or cancer.
An optical cavity includes a plurality of mirrors that reflect light along a closed path. First and second mirrors of the plurality of mirrors define an optical axis therebetween. The optical cavity includes first and second lenses located between the first and second mirrors along the optical axis. A mode of the optical cavity has a waist located between the first and second intracavity lenses. Small values of the waist (e.g., <10 microns) produce large cooperativities that relax requirements for the cavity finesse (i.e., reflectivity of the mirrors). The mirrors may be retroreflecting to create a Fabry-Perot cavity. Alternatively, the first and second mirrors may define one segment of a ring cavity. The optical cavity may be used to trap, read, entangle, and drive nonlinear emitters (e.g., atoms, color centers, quantum dots) located near the waist.
The invention provides method for igniting pressurized fuel, the method comprising placing fuel into a combustion chamber; mixing the fuel with supercritical carbon dioxide and oxidizer to create a mixture; and contacting the fuel-air mixture with a laser, whereby the laser is pointed to a first point within the chamber. Also provided is a laser ignitor for carbon dioxide combustors, the ignitor comprising: an elongated housing capable of varying in length, the housing having a first proximal end and a second distal end; a laser head in close spatial relationship to the proximal end, wherein the laser head generates a first laser beam; a seal at the distal end that is optically transparent to the laser beam and physically opaque to combustion contaminants; an algorithm for directing the first beam to a first point within a combustion chamber for a first period of time; and an algorithm for directing a second laser beam to a second point within the combustion chamber for a second period of time.
Described herein are polymersomes (PSs) as a delivery platform that display enhanced macromolecular encapsulation efficiency with facile, streamlined processing. The formulations herein demonstrate rapid assembly of near-monodisperse PSs without organic solvents to circumvent purification issues. This is achieved through two design principles: 1) temperature responsive PS assembly and 2) affinity-driven payload encapsulation. The BCPs are solubilized in aqueous buffer when refrigerated (4 °C) but self-assemble at room temperature (20 °C) into homogeneous PSs. This is achieved by incorporating polymers segments with a lower critical solution temperature (LCST) below room temperature but above the freezing point of water. BCPs are dissolved alongside a hydrophilic payload, and their uniform self-assembly bypasses solvent and size-exclusion purifications.
C08G 81/00 - Composés macromoléculaires obtenus par l'interréaction de polymères en l'absence de monomères, p. ex. polymères séquencés
C08L 33/06 - Homopolymères ou copolymères des esters d'esters ne contenant que du carbone, de l'hydrogène et de l'oxygène, l'oxygène, faisant uniquement partie du radical carboxyle
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
Systems and methods for delivering a drug to a patient's kidney. The present systems comprise a urethral catheter and a ureteral catheter sized to fit through the urethral catheter. The urethral catheter includes a balloon configured to be inflated in the patient's bladder to retain the urethral catheter in the patient's urethra. The ureteral catheter includes a balloon configured to be inflated in the patient's ureter and/or kidney while a distal end of the ureteral catheter is disposed in the patient's kidney. The ureteral catheter balloon can help retain liquid in the kidney to enable expanded contact areas with kidney tissues and extended dwell times (e.g., periods of exposure) of the drug in the kidney. The balloons also help retain the catheters in the patient's urinary tract, such that the catheter system can be used to deliver a drug to the patient's intermittently or periodically over a period of days or weeks.
A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
8.
DIAMOND MATERIALS WITH REDUCED HYDROGEN-PASSIVATED DEFECTS AND ASSOCIATED FABRICATION METHODS
The present disclosure includes an arm support for supporting a patient's arm during a procedure, such as a cardiac catheterization procedure. Some arm supports include a unitary body defining: a lower portion, an upper portion, a first end, a second end, a proximal side, and a distal side of the arm support, where the lower portion of the unitary body defines a mount configured to be coupled to a patient support, and where the upper portion of the unitary body defines a support surface extending between the first and second ends, where the support surface is shaped to support a patient's arm.
Disclosed are compositions and methods useful for cancer treatment. The composition and methods include overexpressing BAMBI in a population of immune cells, such as myeloid-derived suppressor cells, in order to improve the immune cells immunogenic and/or anti-tumor effects. Also disclosed are compositions and methods for determining responsiveness to a radiotherapy and/or immunotherapy.
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/078 - Cellules du sang ou du système immunitaire
11.
COMPOSITIONS, KITS, AND METHODS FOR ASSESSING MICROBIOME HEALTH
The present disclosure provides compositions and methods related to microbiome health. In particular, the present disclosure provides novel compositions, kits, and methods for treating and/or monitoring the microbiome health of a subject using metabolic biomarkers.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
UNIVERSITY OF CHICAGO (USA)
LEIDOS BIOMEDICAL RESEARCH, INC. (USA)
SCHRODINGER, INC. (USA)
CURIA GLOBAL, INC. (USA)
Inventeur(s)
Stott, Gordon
Green, Neal
Eckert, Mark
Allega, Maria Francesca
White, Andrew
Wolf, Mark Allan
Abrégé
NN-methyltransferase (NNMT) which have a triazolone-piperidine scaffold. The NNMT inhibitors are useful for treating tumors and cancers, metabolic disorders and liver disorders.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
13.
SYSTEMS AND METHODS FOR OPTIMIZED PULSES FOR CONTINUOUS QUANTUM GATE FAMILIES THROUGH PARAMETER SPACE INTERPOLATION
A quantum computing system for optimizing instructions of a quantum circuit is configured to: select reference points in a parameter space of a family of gates that are executable by the quantum processor; identify edges in the parameter space connecting two reference points; compute a pulse vector for each reference point of the plurality of reference points; optimize the pulse vector for each reference point of the plurality of reference points based on the first pulse vector of each neighboring reference point connected to that reference point by an edge; receive a target operation from the quantum circuit for optimization; compute a second pulse vector for the target operation based on interpolating between a subset of reference points of the plurality of reference points; and executed the target operation on a quantum processor using the pulse vector for the target operation.
A battery that cycles lithium ions includes a negative electrode, a positive electrode spaced apart from the negative electrode, and an electrolyte infiltrating the positive electrode. The positive electrode includes a high-voltage positive electrode material. The electrolyte includes an organosulfur compound, a fluorinated aromatic co-solvent, a solid electrolyte interphase (SEI) former, and at least one lithium salt.
H01M 10/0569 - Matériaux liquides caracterisés par les solvants
H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p. ex. liants, charges
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
H01M 10/0567 - Matériaux liquides caracterisés par les additifs
15.
Compositions and Methods Using Lactulose for Treating Disease
In some aspects, provided herein are methods for treating a liver disease or associated condition in a subject, and related compositions. In some embodiments, the composition comprises lactulose and a commensal organism, such as a commensal bacterial species. In some embodiments, the patient has been determined to have a microbiome profile and metabolic profile in a fecal sample from the patient, which may be indicative that the patient will benefit from the treatment.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
16.
LOW-DOSE TOCILIZUMAB FOR THE TREATMENT OR PREVENTION OF SICKLE CELL CRISIS
Provided herein are methods for the treatment or prevention of sickle cell crisis and symptoms associated therewith by the administration of low doses of tocilizumab to a subject. In particular embodiments, provided herein are pharmaceutical compositions comprising doses of 200 mg or less of tocilizumab and methods for the treatment or prevention of sickle cell crisis and symptoms or other conditions arising as a result thereof.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
17.
FUNCTIONALIZED NANOPARTICLES FOR THE CONTAINMENT AND CLEARANCE OF PATHOGENS
Functionalized nanoparticles for inhibiting or preventing pathogen infections (e.g., viral or bacterial infections, such as coronavirus infections) are described. The nanoparticles comprise a biodegradable polymer core and a lipid coating layer that is functionalized with a pathogen-binding receptor (e.g., an angiotensin-converting enzyme 2 (ACE2) receptor protein) and/or a pathogen-binding antibody or an antigen-binding fragment thereof (e.g., a virus-binding antibody or an antigen-binding fragment thereof). The nanoparticles are further functionalized by a phagocyte-specific ligand, e.g., a phosphatidylserine-containing lipid included in the lipid coating layer, to promote clearance of nanoparticle-bound pathogen. Methods of using the nanoparticles to treat or prevent pathogen infections (e.g., coronavirus infections) are also described.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
Aspects of the present disclosure are directed to growth hormone receptor (GHR)-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such GHR-targeting polypeptides and cells comprising such nucleic acids. Described are methods for treatment of acromegaly using GHR-targeting polypeptides.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
Example embodiments allow for networks of hybrid controllers that can be computed efficiently and that can adapt to changes in the system(s) under control. Such a network includes at least one hybrid controller that includes a dynamic sub-controller and a learned system sub-controller. Information about the ongoing performance of the system under control is provided to both the hybrid controller and to an over-controller, which provides one or more control inputs to the hybrid controller in order to modify the ongoing operation of the hybrid controller. These inputs can include the set-point of the hybrid controller, one or more parameters of the dynamic controller, and an update rate or other parameter of the learned system controller. The over-controller can control multiple hybrid controllers (e.g., controlling respective sub-systems of an overall system) and can, itself, be a hybrid controller.
G05B 13/02 - Systèmes de commande adaptatifs, c.-à-d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques
G05B 13/04 - Systèmes de commande adaptatifs, c.-à-d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques impliquant l'usage de modèles ou de simulateurs
Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Girdle Muscular Dystrophy.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
21.
CYCLIC SULFUR CONTAINING ADDITIVE COMPOUNDS FOR HIGH VOLTAGE ENERGY STORAGE DEVICE ELECTROLYTES, AND PROCESSES THEREOF
Provided herein are cyclic sulfite and cyclic sulfate electrolyte additives and formulations for energy storage devices having improved performance. The improved performance may be realized as improved cycling stability at abusive testing conditions.
Systems and methods for generating and manipulating a guided electromagnetic wave in a waveguide are provided. The optical system includes a waveguide, such as a two-dimensional waveguide, and an optical element disposed adjacent the surface of the waveguide. To generate the guided electromagnetic wave, a converging laser beam is generated and coupled to the waveguide by steering the converging laser beam towards an edge of the waveguide and with a beam center trajectory approximately parallel to a surface of the waveguide.
Systems and methods for performing laser lithotripsy include introducing a lithotripsy medium containing nanoparticles into a body cavity comprising target obstructions and applying laser energy through the lithotripsy medium to disrupt the target obstructions. The nanoparticles may have diameters configured to enhance absorption efficiency of the laser energy. The nanoparticles may include organic polymers such as PEDOT: PSS or inorganic compounds such as indium tin oxide. Systems may include a laser source, a fluid delivery component configured to deliver the nanoparticle-containing lithotripsy medium, and an optical fiber for delivering laser energy. Methods of manufacturing lithotripsy media include selecting target wavelengths, synthesizing nanoparticles with corresponding absorption characteristics, and dispersing the nanoparticles at selected concentrations.
A61B 18/24 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes en utilisant des lasers le faisceau étant dirigé le long, ou à l'intérieur d'un conduit flexible, p. ex. d'une fibre optiquePièces à main à cet effet avec un cathéter
A61B 17/22 - Instruments pour comprimer les ulcères ou similaires placés sur les organes internes du corpsInstruments pour curer les cavités des organes du corps, p. ex. des osInstruments, dispositifs ou procédés chirurgicaux pour l'élimination ou la destruction invasives des calculs utilisant des vibrations mécaniquesInstruments, dispositifs ou procédés chirurgicaux pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A lithium ion conducting membrane and methods of making the same. The membrane includes a polymeric matrix and a plurality of ion-conducting particles disposed within the polymeric matrix. An inorganic coating deposited in the polymeric matrix.
An actuator module includes a motor, a flywheel coupled to the motor and configured to be rotated by the motor, a power source, a controller coupled to the power source and the motor, and a housing enclosing the motor, the flywheel, the power source, and the controller. The controller is programmed to operate the motor using the power source in response to instructions received from a remote device.
A63H 30/04 - Agencements électriques par transmission sans fil
A63H 33/08 - Blocs, bandes ou autres éléments pour les jeux de construction assemblés sans emploi de pièces additionnelles pourvus de trous, rainures ou saillies complémentaires, p. ex. queue d'aronde
A method for forming lithium argyrodite composite powders includes providing within an atomic layer deposition (ALD) reactor lithium argyrodite powders of formula Li7−xBCh6−xXx, where 0
C23C 16/455 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour introduire des gaz dans la chambre de réaction ou pour modifier les écoulements de gaz dans la chambre de réaction
C23C 16/30 - Dépôt de composés, de mélanges ou de solutions solides, p. ex. borures, carbures, nitrures
A method of modifying a battery cathode material includes the steps of heating the battery cathode material to a temperature of about 250° C. to about 350° C.; while heating, exposing the battery cathode material to an organometallic gas; and purging the organometallic gas from the battery cathode material, wherein the method removes lithium carbonate from the cathode material surface.
H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
C01G 53/506 - Oxydes complexes contenant du nickel et au moins un autre élément métallique contenant des métaux alcalins, p. ex. LiNiO2 contenant du manganèse du type (MnO2)n-, p. ex. Li(NixMn1-x)O2 ou Li(MyNixMn1-x-y)O2 contenant du lithium et du cobalt avec le rapport molaire du nickel par rapport à tous les métaux autres que les métaux alcalins supérieur ou égal à 0,5, p. ex. Li(MzNixCoyMn1-x-y-z)O2 avec x ≥ 0,5 avec le rapport molaire du nickel par rapport à tous les métaux autres que les métaux alcalins supérieur ou égal à 0,8, p. ex. Li(MzNixCoyMn1-x-y-z)O2 avec x ≥ 0,8
H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p. ex. LiNiO2, LiCoO2 ou LiCoOxFy
28.
HYDRATED SOLID IONIC CHANNELS FOR RARE EARTH ELEMENT SEPARATION AND RECOVERY
Methods of separating rare earth elements, such as lanthanides, from an aqueous solution that includes two or more different types of rare earth elements are provided. The methods use confined solid ionic channels in layered, mixed metal oxides to separate different rare earth ions based on hydration shell size, dehydration energy, binding affinity, and/or hydration phase transformations.
Because of its myeloid-specific expression, it was hypothesized that CD200R could provide both an inhibitory signal and a target for antigen delivery to antigen presenting cells if antigens are fused recombinantly to a soluble CD200. The examples demonstrate that immunological tolerance can be established using antigen-fused CD200 molecules, including CD200Fc- fused antigen. This tolerance was demonstrated by abrogating responses to immune challenge and induction of production of tolerogenic cytokines, including IL- 10. Accordingly, the polypeptides, compositions, and methods are useful for tolerization of any antigen, such as any antigen related to autoimmune conditions, allergy conditions, anti-drug immunity conditions, among others. Described here is a polypeptide comprising a CD200 polypeptide operatively linked to an antigen. Also provided is a nucleic acid encoding a polypeptide, an expression vector comprising a nucleic acid of the disclosure, host cells comprising a polypeptide of the disclosure. Also described are methods utilizing the polypeptides and compositions.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/00 - Préparations médicinales contenant des peptides
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
Systems and methods are disclosed for predicting the rise of different strains of viruses. A method comprises reading a genetic sequence of a first strain of a virus; identifying a plurality of residue indices in the genetic sequence; for each of the plurality of indices, assigning a predictor, the predictor configured to predict a residue for its assigned index based upon a residue of at least one other index, the predictors thereby forming a network; and determining, based on the network of predictors, a probability of transition of the first strain to a second strain.
G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p. ex. de la grippe
G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
31.
COMPOSITIONS AND METHODS RELATED TO MODIFICATION AND DETECTION OF PSEUDOURIDINE AND 5-HYDROXYMETHYLCYTOSINE
Aspects of the present disclosure are directed to methods and compositions for modification, detection, and quantification of pseudouridine and 5-hydroxymethylcytosine. Disclosed are methods for modification of pseudouridine and/or 5-hydroxymethylcytosine comprising bisulfite treatment under particular conditions. Further disclosed are compositions and kits comprising a bisulfite solution and instructions for use.
The Board of Trustees of the University of Illinois (USA)
Inventeur(s)
Weber, Christopher R.
Shen, Le
Khalili-Araghi, Fatemeh
Abrégé
Provided is a method of treating a disorder mediated by claudin-2 and/or claudin-15, particularly an intestinal disorder, such as colitis or enteritis. The method comprises administering to the subject an effective amount of a compound of formula (I), formula (II), or otherwise as described herein or a pharmaceutically acceptable salt thereof. In another aspect, also provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof.
C07D 239/06 - Composés hétérocycliques contenant des cycles diazine-1, 3 ou diazine-1, 3 hydrogéné non condensés avec d'autres cycles comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique
A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
A61K 31/17 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61K 31/536 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines condensées en ortho ou en péri avec des systèmes carbocycliques
C07D 233/24 - Radicaux substitués par des atomes d'azote ne faisant pas partie d'un radical nitro
33.
MATERIALS AND METHODS FOR LARGE-SCALE SPATIAL TRANSCRIPTOMICS
The present disclosure relates to materials and methods for large-scale spatial transcriptomics. In particular, the disclosure provides methods for producing systems for spatial transcriptomics, along with materials and methods for determining the spatial location of a desired nucleic acid, such as RNA, within a tissue sample.
Provided herein are electrolyte additives and formulations for energy storage devices having improved performance. The improved performance may be realized as improved cycling stability at abusive testing conditions.
H01M 10/0567 - Matériaux liquides caracterisés par les additifs
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
35.
METHODS AND COMPOSITIONS FOR ACTIVATING TRANSLATION
The current disclosure relates to nucleic acid therapeutics that target mRNA molecules and recruit translation machinery to increase the translation from the mRNA, thus increasing the protein product in a subject or cell. Accordingly, aspects of the disclosure relate to a chimeric nucleic acid comprising a targeting region and a translational activating region, wherein the translational activating region comprises at least one ribosome and/or translation factor binding site and wherein the targeting region comprises a region that is complementary to a target mRNA. Further described are circular nucleic acids comprising a targeting region and a translational activating region, wherein the translational activating region comprises at least one ribosome and/or translation factor binding site and wherein the targeting region comprises a region that is complementary to a target mRNA.
A structured illumination microscopy system includes a plurality of lights sources. Each light source emits an excitation beam. The excitation beams vary in wavelength. The system also includes a plurality of dichroic mirrors positioned to collimate the excitation beams emitted from the plurality of light sources into a multicolor beam. A blazed grating is positioned to receive the multicolor beam and to disperse the multicolor beam into a plurality of monochrome beams. The blazed grating directs the monochrome beams toward a digital micromirror device, which is positioned to receive the plurality of monochrome beams from the blazed grating and to direct the plurality of monochrome beams toward a sample. An image sensor is positioned between the digital micromirror device and the sample. The image sensor generates an image of the sample based at least in part on an interaction of the plurality of monochrome beams and the sample.
A coherence model predicts the coherence time of one spin qubit based on decoherence caused by a surrounding spin bath. This coherence model, which is constructed by performing cluster correlation expansion calculations of spin-bath-induced decoherence, includes a library of coherence time distributions over a parameter-space range. Using this library, maximum likelihood estimation is then performed on a set of experimental data, enabling the density of the spin bath and the dimensionality of the spin qubits to be determined, given certain geometrical constraints. Rather than relying on assumptions that average over interactions between bath spins and central qubit spins, the present embodiments simulate the dynamics of the entire interacting spin bath, producing a quantum mechanical characterization technique for quantum applications that can be incorporated into a feedforward synthesis loop.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
G01N 24/12 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance double
G06N 10/20 - Modèles d’informatique quantique, p. ex. circuits quantiques ou ordinateurs quantiques universels
G06F 30/3308 - Vérification de la conception, p. ex. simulation fonctionnelle ou vérification du modèle par simulation
G06N 10/80 - Programmation quantique, p. ex. interfaces, langages ou boîtes à outils de développement logiciel pour la création ou la manipulation de programmes capables de fonctionner sur des ordinateurs quantiquesPlate-formes pour la simulation ou l’accès aux ordinateurs quantiques, p. ex. informatique quantique en nuage
G06N 10/00 - Informatique quantique, c.-à-d. traitement de l’information fondé sur des phénomènes de mécanique quantique
Technologies for resource-efficient quantum error correction are disclosed. A quantum computer may include physical gate qubits, capable of general quantum gate operations such as single-qubit operations and nearest-neighbor two-qubit operations. Each physical qubit gate may be controllably coupled to a quantum memory. The quantum memory may have a lower per-gate error rate than the physical qubit gates as well as a lower per-qubit cost. Because errors accrue at a lower rate in the quantum memory, the physical gate qubits may be able to perform error correction for a large number of logical qubits in the quantum memory, even if the physical gate qubits have an error rate relatively close to an error threshold.
G06N 10/70 - Correction, détection ou prévention d’erreur quantique, p. ex. codes de surface ou distillation d’état magique
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Delferro, Massimiliano
Ferrandon, Magali S.
Poeppelmeier, Kenneth R.
Sadow, Aaron D.
Scott, Susannah
Lapointe, Anne M.
Coates, Geoffrey
Abrégé
A method of upcycling polymers to useful hydrocarbon materials. A catalyst with nanoparticles on a substrate selectively docks and cleaves longer hydrocarbon chains over shorter hydrocarbon chains. The catalyst includes metal nanoparticles in an order array on a substrate.
B01J 35/23 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général caractérisés par leur état non solide sous forme colloïdale
Provided herein are methods of preparing an immunotherapeutic with enhanced efficacy by treating lymphocytes with a B-cell lymphoma 2 (BCL-2) inhibitor, immunotherapeutic compositions produced by the methods herein, and methods of treating cancer therewith.
Aspects of the present disclosure are directed to synthetic DNA binding peptides, as well as methods of generating such peptides and methods for use of such peptides in, for example, DNA binding, modifying gene expression, and treatment of various conditions such as cancer, fibrosis, and diabetes. Certain aspects provide synthetic DNA binding dimers comprising two modified bZIP peptides, each comprising a modified basic domain and a modified leucine zipper domain and linked via an interpeptide linker (e.g., a side-by-side interpeptide linker). Also disclosed are universal methods for generating high affinity synthetic DNA binding dimers from any bZIP protein.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
Aspects of the present disclosure are directed to borealin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such borealin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using borealin-targeting polypeptides.
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
44.
DESIGNING BACTERIAL COMMUNITIES USING MACHINE LEARNING
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for training a machine learning model that is configured to process a model input that defines a bacterial community to generate a predicted score that predicts a performance of the bacterial community in performing a bacterial task. According to one aspect, a method comprises: generating data identifying a set of bacterial communities; obtaining, for each bacterial community, a target score for the bacterial community; generating a set of training examples, wherein each training example corresponds to a respective bacterial community and comprises: (i) a training input that identifies the bacterial strains included in the bacterial community, and (ii) the target score for the bacterial community; training the machine learning model on the set of training examples; and identifying one or more candidate bacterial communities for performing the bacterial task using the trained machine learning model.
The present disclosure provides macrocyclic and macrobicyclic peptides with secondary structures that are stabilized over the corresponding non-cyclic peptides. The macrocyclic and macrobicyclic peptides are formed from peptides with adduct-forming, complementary reactive side chain moieties.
A new type of multi-bit and energy-efficient magnetic memory based on current-driven, field-free, and highly controlled domain wall motion is disclosed. A meandering domain wall magnetic channel with precisely interspersed pinning regions provides the multi-bit capability. The magnetic free layer of the memory device has a perpendicular magnetic anisotropy and interfacial Dzyaloshinskii-Moriya interaction, so that spin-orbit torques induce efficient domain wall motion. Example pinning mechanisms of the domain wall corresponding to various magnetic memory cell designs are further disclosed, including a two-way switching mechanism and a four-way switching mechanism as examples. A synthetic antiferromagnetic stack is further designed to function as the free magnetic layer, giving rise to improvement in operation speed and reliability and reduction of the domain wall tilting.
G11C 11/155 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage électriques ou magnétiques particuliersÉléments d'emmagasinage correspondants utilisant des éléments magnétiques utilisant des éléments à pellicules minces avec une configuration cylindrique
G11C 11/02 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage électriques ou magnétiques particuliersÉléments d'emmagasinage correspondants utilisant des éléments magnétiques
G11C 11/16 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage électriques ou magnétiques particuliersÉléments d'emmagasinage correspondants utilisant des éléments magnétiques utilisant des éléments dans lesquels l'effet d'emmagasinage est basé sur l'effet de spin
47.
WEARABLE SENSOR SYSTEM FOR DETECTING AND MONITORING RESPIRATION
An example of a physiological monitoring system includes a sensor system configured to be worn by a subject. The sensor system can include a compliant substrate, a sensor array arranged on the compliant substrate, a sensor module, and an electronic control system communicatively coupled to the sensor system. The sensor system can be configured to obtain sensor data representing a physiology of the subject, and transmit the sensor data to the electronic control system. The sensor data can include one or more first audio signals generated by a plurality of microphones of the sensor array and one or more second audio signals generated by an ambient microphone of the sensor module. Further, the electronic control system can be configured to receive the sensor data from the sensor system and, pre-process the sensor data, which in turn can include generating a respiratory waveform based on the pre-processed sensor data.
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. (Allemagne)
Inventeur(s)
Lengyel, Ernst
Mann, Matthias
Curtis, Marion
Coscia, Fabian
Abrégé
The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
The invention provides an automated method for isolating a targeted isotope, the method having the steps of supplying a dissolved uranium targets into a first reaction environment; precipitating non-targeted isotope within the first reaction environment transferring liquid phase targeted isotope to a second reaction environment; precipitating the liquid phase targeted isotope in the second reaction environment; dissolving the precipitated targeted isotope; transferring the dissolved targeted isotope to a third reaction environment; and precipitating non-targeted isotope (i.e., iodine), such that the targeted isotope remains in the solution. Also provided is an automated system for isolating isotopes, the system having a plurality of reaction environments adapted to pneumatically receive and disgorge reactants and products via remotely actuated valves positioned between each of the reaction environments.
G21G 1/00 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs
51.
COMPOSITIONS AND METHODS FOR REPLICON-MEDIATED GENE THERAPY
SindbisSindbis RNA replicons or Venezuelan equine encephalitis (VEE) replicons, can stabilize the longevity of the RNA replicon and can stabilize the expression of the cargo proteins encoded by the self-replicating RNA molecule or RNA replicon. Also disclosed herein are compositions and methods directed to the discovery that certain viral proteins, including viral proteins that repress internal cellular innate immunity, can stabilize the payload expression and replication of the replicons. Technologies provided herein provide stabilization mechanisms that can improve vaccines, gene therapies, and/or other gene delivery methods.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
The present disclosure relates to combination treatments for cancer. Specifically, the present disclosures relates to combination treatment of neuroendocrine tumors with an inhibitor of estrogen signaling or a retinoid, and radiation therapy or targeted radionuclide therapy.
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/502 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. cinnoline, phtalazine
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
Aspects of the present disclosure are directed to at least methods and compositions for diagnosis and/or treatment of diseases associated with aberrant levels of m5C RNA, including but not limited chromatin associate RNA (caRNA). The disease may comprise cancer and/or pre-cancerous cells. The disease may be associated with mutations in a TET2 pathway, including but not limited to mutations in TET2, IDH1, IDH2, and/or ASXL1 encoding genes. Treatment of a disease may comprises administration of one or more inhibitors of MBD6, TET2, and/or NSUN2. Also provided herein are methods of treatment of a disease in an individual comprising administering one or more inhibitors of MBD6, TET2, and/or NSUN2 to the individual determined to have aberrant m5C RNA modifications.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c.-à-d. autres que des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
A method can include providing two or more parts. The two or more parts can include a first part and a second part. The method can include disposing a source material between the first part and the second part. The method can include joining and densifying the first part and the second part by reacting a liquid with the source material.
B29C 65/48 - Assemblage d'éléments préformésAppareils à cet effet en utilisant des adhésifs
B23P 15/26 - Fabrication d'objets déterminés par des opérations non couvertes par une seule autre sous-classe ou un groupe de la présente sous-classe d'échangeurs de chaleur
B29L 31/18 - Échangeurs de chaleur ou leurs parties constitutives
A high-resolution x-ray reflectometer system that is for characterization of mirrors for use with advanced light sources and includes a table, arc, and sample stage. The table and arc may be made of the same material, in some configurations that material is granite. An x-ray source and detector are mounted on the arc. The arc is movable along the surface of the table in a first direction, and the sample stage is moveable on the table surface in a second direction, perpendicular to the first direction. The sample stage can accommodate a sample with a thickness of 5 cm or more. Vertical lifting stages at each end of the sample stage allow for independent height adjustment of the ends, allowing for tiling of the sample. An autocollimator is mounted at the apex of the arc to characterize the tilt of a sample on the sample stage.
G01N 23/20008 - Détails de construction des appareils d’analyse, p. ex. caractérisés par la source de rayons X, le détecteur ou le système optique à rayons XLeurs accessoiresPréparation d’échantillons à cet effet
56.
COMPOSITIONS AND METHODS FOR DETERMINING PROTEIN INTERACTIONS
Embodiments of the disclosure may comprise a photo-dependent proximity labeling system comprising an activatable probe and a retrievable substrate. The activatable probe may be, for example, an integrin binding peptide operatively coupled to a lumichrome molecule, and the retrievable substrate may be, for example, a biotin phenol. In some aspects, the activatable probe is activatable by light, thereby inducing labeling of adjacent molecules with a retrievable substrate. Also disclosed are methods for labeling proteins, identifying protein interactions or binding partners, and methods for identifying a therapeutic target in an individual using a composition of the disclosure.
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
Employing undulator devices as x-ray radiation sources requires high magnetic field strength and precision for generating high intensity, high coherence radiation. A magnetic field tunable undulator device is described. The undulator device includes a first magnet array disposed along a central axis of the undulator device, and a second magnet array disposed along the central axis, opposite the first magnetic array, across a gap distance. First and second structural keepers are respectively coupled to the first and second magnetic arrays to support positions of the first and second magnet arrays. A plurality of tuning elements are (i) disposed along the central axis, (ii) physically coupled to at least one of the first magnet array or the second magnet array, and (iii) configured to tune the magnetic field profile along the central axis between the first magnet array and the second magnet array.
Typical chemical vapor deposition (CVD) systems are unable to analyze a sample during CVD fabrication. A system and method for performing material deposition and in-situ analysis of a sample during CVD synthesis is described. The system includes a deposition chamber having an outer chamber wall surrounding a chamber volume and an inner sleeve disposed inside of the chamber volume with a buffer region between the outer chamber wall and the inner sleeve. A sample mount is disposed in the deposition volume to support a position and orientation of a sample in the deposition volume during CVD. Gas inlets and gas outlets are in fluid communication with the deposition chamber to respectively allow fluid to flow into, and out of, the deposition chamber. A thermal radiation source provides thermal radiation along a deposition axis to the sample disposed in the deposition volume.
C23C 16/48 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement par irradiation, p. ex. par photolyse, radiolyse ou rayonnement corpusculaire
C23C 16/54 - Appareillage spécialement adapté pour le revêtement en continu
G01N 23/20008 - Détails de construction des appareils d’analyse, p. ex. caractérisés par la source de rayons X, le détecteur ou le système optique à rayons XLeurs accessoiresPréparation d’échantillons à cet effet
59.
SURFACE CLEANING, MODIFICATION AND DOPING OF ARGYRODITE TYPE SOLID ELECTROLYTES
A method for modifying argyrodite-type material. The argyrodite-type material is exposed to a fluorine precursor. The argyrodite-type material may have a carbonate coating that has formed, such as due to exposure to air, with such carbonate coating at least partially removed by exposure to the fluorine precursor. The argyrodite-type material may further be doped by fluorine after exposure to the precursor. Further, the argyrodite-type material may have a capping layer formed thereon.
C23C 16/44 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement
C23C 16/455 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour introduire des gaz dans la chambre de réaction ou pour modifier les écoulements de gaz dans la chambre de réaction
60.
Method for Improved Heavy Metal Wetting on a Surface
A method for coating a coolant metal on a ceramic substrate comprises modification of the substrate surface to provide an oxide free surface upon which the coolant metal is deposited.
C23C 2/02 - Pré-traitement du matériau à revêtir, p. ex. pour le revêtement de parties déterminées de la surface
C23C 14/06 - Revêtement par évaporation sous vide, pulvérisation cathodique ou implantation d'ions du matériau composant le revêtement caractérisé par le matériau de revêtement
C23C 14/18 - Matériau métallique, bore ou silicium sur d'autres substrats inorganiques
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for predicting a property of an input biological entity. The system generates an evolutionary feature representation of the input biological entity based at least in part on an evolutionary tree, and processes a model input that comprises the evolutionary feature representation sing a machine learning model to generate the prediction for the property of the input biological entity.
Systems and methods are provided herein for training a customized model. A method of constructing a customized generative model, comprising reading a plurality of synthetic images and associated latent representations; presenting each of the plurality of synthetic images to one or more users via a client computing platform; reading a plurality of inputs characterizing a plurality of values for a plurality of associated attributes of each of the plurality of synthetic images; based on the values of the associated attributes and the latent representations, training a regression model to predict the values of the attributes from the latent representations.
G06V 10/774 - Génération d'ensembles de motifs de formationTraitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source méthodes de Bootstrap, p. ex. "bagging” ou “boosting”
G06V 10/766 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la régression, p. ex. en projetant les caractéristiques sur des hyperplans
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 10/94 - Architectures logicielles ou matérielles spécialement adaptées à la compréhension d’images ou de vidéos
63.
SELECTIVE AND LONG-LIVED SINGLE COMPONENT HETEROGENEOUS ETHYLENE TRIMERIZATION CATALYSTS ENABLED BY SURFACE LITHIATION
A catalyst for selective hexane and/or butene formation from ethylene. The catalyst is formed by grafting Cr or Mn to an inorganic support. The grafted metal site is reduced, forming a catalyst that is selective for selective trimerization of ethylene to hexene and/or butene.
Methods, compositions and kits are provided to amplify an amount of genomic methylated DNA that can be subsequently analyzed and/or sequenced. It has particular use with small amounts of DNA, including, but not limited to cell free DNA samples. In some embodiments, the ratio of polymerase and methyltransferase is controlled in order to provide maximum yields. In some embodiments, a dual primase/polymerase is used.
In aspects, the present disclosure provides a method of treating or preventing premature ovarian insufficiency or polycystic ovary syndrome in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of (i) mesenchymal stem cells (MSCs) or secretome from MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); (ii) exosomes produced by MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); and/or (iii) exosomes comprising one or more effectors, wherein the one or more effectors comprises, consists essentially of, or consists of (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d), and wherein the amount of the effector per exosome is greater than the amount of the effector per exosome when produced by unmodified MSCs. In aspects, the present disclosure provides a method of preparing MSCs, exosomes, and secretome. In aspects, the present disclosure provides a method of preventing chemotherapy-induced damage in a male mammal.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
Provided herein are methods for extracting and separating metals from a mixture of metal oxides comprising: disposing a cathode comprising the mixture of metal oxides, a reducing electrode, and an anode in a solvent comprising a mixture of molten metal hydroxide salts; applying an electrical potential to a cathode, thereby reducing the mixture of metal oxides and forming a mixture of metals; selectively dissolving one or more metal ion species from the mixture of metals into the dried solvent; and applying a potential to the reducing electrode present in the dried solvent to reduce the dissolved metal ion species from the dried solvent to a respective pure metal or mixed metal.
A shredder for minimizing aggregation of whole batteries can include a shaft defining a longitudinal axis and a latitudinal axis. The shredder can include a plurality of teeth disposed on knives which fit on said shaft at an angle to the latitudinal axis selected from 0 degrees and 45 degrees. The teeth can have a first proximal end integrally molded to the shaft and a second free distal end.
H01M 10/54 - Récupération des parties utiles des accumulateurs usagés
B02C 18/08 - Désagrégation par couteaux ou autres organes coupants ou déchirants qui transforment le matériau en fragmentsHachoirs ou appareils similaires utilisant des vis ou analogue à couteaux rotatifs à l'intérieur de récipients verticaux
B02C 18/14 - Désagrégation par couteaux ou autres organes coupants ou déchirants qui transforment le matériau en fragmentsHachoirs ou appareils similaires utilisant des vis ou analogue à couteaux rotatifs à l'intérieur de récipients horizontaux
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
THE UNIVERSITY OF CHICAGO (USA)
Inventeur(s)
Simon, Jonathan
Schuster, David I.
Taneja, Lavanya
Abrégé
An optical resonator includes a plurality of mirrors positioned to reflect light along a closed path, thereby defining an optical axis. The optical resonator also includes one or more intracavity lenses positioned along the optical axis to establish a resonator mode whose waist that is located along the optical axis. The optical resonator also includes an intracavity nonlinear optical element that implements a nonlinear frequency-mixing process within the optical resonator. When input light is coupled into the optical resonator to excite the resonator mode, the intracavity nonlinear optical element nonlinearly converts at least some of the input light into nonlinearly generated light. This nonlinearly generated light may then be coupled out of the optical resonator, such as via transmission through one of the mirrors. In some embodiments, the waist is five microns or less. In some embodiments, the finesse of the optical resonator is 100 or less.
G02F 1/355 - Optique non linéaire caractérisée par les matériaux utilisés
G02F 1/37 - Optique non linéaire pour la génération de l'harmonique deux
G02F 1/39 - Optique non linéaire pour la génération ou l'amplification paramétrique de la lumière, des infrarouges ou des ultraviolets
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p. ex. couplage ou commande de qubit
69.
SILYL ENOLATES FOR USE IN LITHIUM BATTERY ELECTROLYTES
A non-aqueous electrolyte comprising a salt, a non-aqueous solvent, and a compound of Formula (I) or Formula (II) or Formula (III) or Formula (IV) or Formula (V):
A non-aqueous electrolyte comprising a salt, a non-aqueous solvent, and a compound of Formula (I) or Formula (II) or Formula (III) or Formula (IV) or Formula (V):
H01M 10/0567 - Matériaux liquides caracterisés par les additifs
C07F 7/18 - Composés comportant une ou plusieurs liaisons C—Si ainsi qu'une ou plusieurs liaisons C—O—Si
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
H01M 10/42 - Procédés ou dispositions pour assurer le fonctionnement ou l'entretien des éléments secondaires ou des demi-éléments secondaires
70.
ELECTROLYTES FOR HIGH CAPACITY SILICON-BASED ANODE BATTERIES
An electrochemical cell includes an anode comprising silicon and an electrolyte comprising a linear carbonate and vinylene carbonate in a concentration of about 11 wt. % to about 80 wt. % based on the weight of the electrolyte. The electrolyte is free of saturated cyclic carbonates conventionally used in lithium-ion batteries.
Employing undulator devices as x-ray radiation sources requires expensive and bulky support systems for operation, which are not robust and lead to limited ranges of generated radiation energies. A force-compensated undulator device is described. The device includes an undulator having first and second magnet arrays disposed along a central axis. The first magnet array is translatable along the central axis. The device further includes a compensator unit disposed adjacent to the first magnet array with the compensator unit having a first row of magnets disposed along a compensator axis with the compensator axis being parallel to the central axis, and a second row of magnets disposed along the compensator axis. The first row of magnets is translatable along the compensator axis. The compensator provides magnetic forces that neutralize the system dynamic magnetic forces generated by the undulator.
H01S 3/0959 - Procédés ou appareils pour l'excitation, p. ex. pompage utilisant le pompage par des particules de haute énergie par un faisceau d'électrons
The present document relates to systems and methods that implement acoustofluidics to manipulate particles within a microfluidic system. The method comprising delivering the sample through a first microchannel, wherein the sample comprises a first population of entities having a first characteristic and a second population of entities having a second characteristic that is different than the first characteristic; applying an acoustic wave through at least a portion of the first microchannel, thereby generating displacement of at least a portion of the first and second populations traveling through the first microchannel by way of acoustic radiation force and acoustic streaming; and separating the sample into a first separated population and a second separated population, wherein the first separated population comprises a majority of entities having the first characteristic and wherein the second separated population comprises a majority of entities having the second characteristic.
Aspects of the present disclosure are directed to methods, compositions, and kits for detection and analysis of DNA and RNA cytosine methylation. Certain aspects include methods, compositions and kits useful in bisulfite sequencing of methylated nucleic acids, including methylated nucleic acids from low-input samples such as cell-free DNA and cell-free RNA. Also disclosed are methods and compositions for detection and quantification of 5-hydroxymethylcytosine in DNA.
A polymer comprising a plurality of repeat units of formula (I)
A polymer comprising a plurality of repeat units of formula (I)
A polymer comprising a plurality of repeat units of formula (I)
or formula (IV)
A polymer comprising a plurality of repeat units of formula (I)
or formula (IV)
A polymer comprising a plurality of repeat units of formula (I)
or formula (IV)
wherein each Ar1 and Ar4 is a unit comprising two or more aromatic groups; Ar1 comprises at least one cross-linkable group; Ar4 comprises a substituent selected from —SO3H, —CO2H, —PO3H2, and salts thereof; R1 and R2, and R7 and R8, are independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, aryl, and heteroaryl, each optionally substituted, or R1 and R2, or R7 and R8, together with the carbon atom to which they are attached, form a carbocycle or heterocycle, provided that at least one of R7 and R8 contains an amide group or at least one geminal pair of R7 and R8, together with the carbon atom to which they are attached, forms a carbocycle or heterocycle that contains an amide group; and membranes and membrane electrode assemblies including same.
C08G 10/00 - Polymères de condensation obtenus uniquement à partir d'aldéhydes ou de cétones avec des hydrocarbures aromatiques ou avec leurs dérivés halogénés
B01J 39/05 - Procédés utilisant des échangeurs organiques sous forme fortement acide
B01J 39/19 - Composés macromoléculaires obtenus autrement que par des réactions ne faisant intervenir que des liaisons carbone-carbone non saturées
B01J 41/05 - Procédés utilisant des échangeurs organiques sous forme fortement basique
B01J 41/13 - Composés macromoléculaires obtenus autrement que par des réactions ne faisant intervenir que des liaisons carbone-carbone non saturées
B01J 47/12 - Procédés d'échange d'ions en généralAppareillage à cet effet caractérisés par l'emploi d'une substance échangeur d'ions sous forme de rubans, de filaments, de fibres ou de feuilles, p. ex. sous forme de membranes
H01M 8/10 - Éléments à combustible avec électrolytes solides
H01M 8/1004 - Éléments à combustible avec électrolytes solides caractérisés par les ensembles membrane-électrodes [MEA]
H01M 8/1027 - Matériaux d’électrolyte polymère caractérisés par la structure chimique de la chaîne principale du polymère conducteur ionique comprenant du carbone, de l’oxygène et d’autres atomes, p. ex. des polyéthersulfones sulfonés [S- PES]
H01M 8/103 - Matériaux d’électrolyte polymère caractérisés par la structure chimique de la chaîne principale du polymère conducteur ionique comprenant de l’azote, p. ex. des polybenzimidazoles sulfonés [S-PBI], des polybenzimidazoles comprenant de l’acide phosphorique, des polyamides sulfonés [S-PA] ou des polyphosphazènes sulfonés
75.
COMPOSITION AND METHODS FOR TUMOR IMAGING AND TREATMENT
Radioisotope-labeled small molecule activity-based probes that target the cancer associated serine hydrolase neutral cholesterol ester hydrolase 1 (NCEH1) are described. The probes can undergo a reaction with the NCEH1, resulting in covalent bonding of a portion of the probe molecule to the NCEH1. Also described are methods of labeling NCEH1 in biological samples, such as cells or tissue, and methods of visualizing tumors using the radioisotope-labeled NCEH1 probes as tracer compounds, either alone or in combination with assessing the efficacy of a cancer treatment or potential cancer treatment.
C07C 271/48 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone de cycles aromatiques à six chaînons avec les atomes d'azote des groupes carbamate liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone de radicaux hydrocarbonés substitués par des atomes d'oxygène liés par des liaisons simples
76.
ESTROGEN RECEPTOR ALPHA ANTAGONISTS AND USES THEREOF
The disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein n, X1, and R'-R3 are defined herein: Also provided are pharmaceutical compositions comprising a compound disclosed herein, methods of inhibiting estrogen receptor alpha (ERa), methods of treating an estrogen- mediated disease in a subject requiring inhibition of estrogen receptor (ER) alpha (ERa), methods of treating one or more symptoms of menopause in a subject in need thereof, and methods of treating one or more side effects of hormone replacement therapy.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
A61K 31/4353 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques
To address the need in the art, the inventors have comprehensively characterized Aspects of the disclosure relate to novel antibody and antigen binding fragments. Further aspects relate to polypeptides comprising the antigen binding fragment(s) of the disclosure, and compositions comprising the polypeptides, antibodies, and/or antigen binding fragments of the disclosure. Also described are nucleic acids encoding an antibody or antigen binding fragment of the disclosure.
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
Provided herein are depolymerizable thermally activated delayed fluorescence polymers with exceptional light-emitting properties and programmable depolymerization under specific stressors.
Lithium-ion cells including fluoroether electrolytes and configured to promote lithium intercalation and (de)intercalation within graphite without fluoroether co-intercalation are provided. Processes for preparing the lithium-ion cells are further provided.
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
H01M 4/02 - Électrodes composées d'un ou comprenant un matériau actif
H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFyEmploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p. ex. phosphates, silicates ou borates
H01M 10/0568 - Matériaux liquides caracterisés par les solutés
H01M 10/0569 - Matériaux liquides caracterisés par les solvants
Systems and methods for generating and manipulating a guided electromagnetic wave in a waveguide are provided. The optical system includes a waveguide, such as a two-dimensional waveguide, and an optical element disposed adjacent the surface of the waveguide. To generate the guided electromagnetic wave, a converging laser beam is generated and coupled to the waveguide by steering the converging laser beam towards an edge of the waveguide and with a beam center trajectory approximately parallel to a surface of the waveguide.
Lymphatic, nervous, and tumoral tissues, among others, exhibit physiology that emerges from three-dimensional interactions between genetically unique cells. A technology capable of volumetrically imaging genotypes and morphologies in a single de novo measurement would therefore provide a critical view into the biological complexity of living systems. The present disclosure achieves this by extending DNA microscopy, an imaging modality that encodes a spatio-genetic map of a specimen via a massive distributed network of DNA molecules inside it, to three dimensions and multiple length scales in developing zebrafish embryos.
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
The present disclosure concerns immunomodulatory compositions and methods of use for enhancing response to an antigen (e.g., in a vaccine), an immunotherapy (e.g., a cancer immunotherapy), or other immune stimulation. The disclosure describes immunomodulators having reduced toxicity and improved immune response compared with existing adjuvants. Further disclosed are methods for improving an immune response to a vaccine antigen, cancer immunotherapeutic, or other immune stimulating agent. The disclosure describes dimeric and polymeric immunomodulators comprising one or more pattern recognition receptor (PRR) agonist moieties and one or more NF-κB inhibitor moieties.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/21 - Retroviridae, p. ex. virus de l'anémie infectieuse équine
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
The invention provides a method for fabricating x-ray focusing optics, the method comprising supplying a first cathode forming a first channel, inserting a substrate within the channel; and charging the first cathode to sputter first cathode material to a surface defining the substrate, thereby forming a first zone film onto the surface. Also provided is a monolithic X-ray diffraction lens having sub 10 nanometer resolutions, the lens comprising a substrate overlaid with discrete regions of metal, the regions integrally molded with the substrate.
G21K 1/06 - Dispositions pour manipuler des particules ou des rayonnements ionisants, p. ex. pour focaliser ou pour modérer utilisant la diffraction, la réfraction ou la réflexion, p. ex. monochromateurs
C23C 14/04 - Revêtement de parties déterminées de la surface, p. ex. au moyen de masques
84.
CONCENTRATED SOLAR POWER ELECTRIC POWER PLANT HEAT EXCHANGE MODULE
An additively manufactured heat exchanger adapted for use in extreme environments, such as a concentrated solar power (CSP) electric power plant. The heat exchanger receives a liquid heat transfer fluid at a high temperature and high pressure. The heat exchanger efficiently exchanges heat with a working fluid flowing in a cross-flow or a counter-flow configuration. A first set of channels of the heat exchanger receives liquid heat transfer fluid, such as corrosive molten salt, and a second set of channels receives working fluid, such as super critical carbon dioxide. The heat exchanger transfers heat from the liquid heat transfer fluid to the working fluid.
F28F 9/02 - Boîtes de distributionPlaques d'extrémité
B22F 1/10 - Poudres métalliques contenant des agents lubrifiants ou liantsPoudres métalliques contenant des matières organiques
B33Y 80/00 - Produits obtenus par fabrication additive
F28F 1/10 - Éléments tubulaires ou leurs ensembles avec moyens pour augmenter la surface de transfert de chaleur, p. ex. avec des ailettes, avec des saillies, avec des évidements
F28F 21/04 - Structure des appareils échangeurs de chaleur caractérisée par l'emploi de matériaux spécifiés de céramiqueStructure des appareils échangeurs de chaleur caractérisée par l'emploi de matériaux spécifiés de bétonStructure des appareils échangeurs de chaleur caractérisée par l'emploi de matériaux spécifiés de pierre naturelle
F28F 21/08 - Structure des appareils échangeurs de chaleur caractérisée par l'emploi de matériaux spécifiés de métal
G06T 17/00 - Modélisation tridimensionnelle [3D] pour infographie
85.
COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE
Aspects of the present disclosure are directed to methods and compositions for generation of antigen-specific regulatory T cells. Certain aspects relate to methods and compositions for generating tolerogenic antigen presenting cells, including tolerogenic dendritic cells. The present disclosure includes compositions, including nanocarrier compositions, comprising TLR agonists, and immunosuppressive agents and optionally an antigen. Also disclosed are methods for use of such compositions in generation of tolerogenic antigen presenting cells and treatment of certain conditions, including autoimmune and inflammatory conditions.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/366 - Lactones ayant des cycles à six chaînons, p. ex. delta-lactones
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
86.
POLYPEPTIDES FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION
Here, the inventors report that natural WT SARS-CoV-2 infection induces memory B cells expressing potently neutralizing antibodies against VOCs. Moreover, natural WT infection largely induced antibodies against spike epitopes outside of the RBD, most of which were non-neutralizing against WT and VOCs. Additionally. RBD-binding antibodies could be categorized into 3 distinct classes based on their binding profiles against RBD mutant constructs. The inventors identified VOC-neutralizing antibodies against three distinct regions of the spike protein, including the two epitopes on the RBD and one epitope in the NTD. Together, this study identifies that natural WT infection induces memory B cells that can produce neutralizing antibodies against recent SARS-CoV-2 VOCs and have the potential to be recalled by vaccination.
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 31/14 - Antiviraux pour le traitement des virus ARN
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
87.
ELECTROLYTE ADDITIVES FOR HIGH PERFORMANCE LITHIUM-SULFUR BATTERIES
A lithium-sulfur battery providing stable, high energy density includes a cathode including sulfur, an anode including lithium metal, and an electrolyte including non-aqueous solvent and an additive including a fluorinated borate or a fluorinated borane; and lithium bis(nonafluorobutanesulfonyl)imide (LiNFBSI).
Aspects of the present disclosure are directed to survivin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such survivin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using survivin-targeting polypeptides.
A process for charging a discharged electrochemical cell includes applying a voltage bias to the discharged electrochemical cell; and illuminating the cathode, the anode, or both the cathode and the anode with light having a narrow band of wavelengths corresponding to the respective band gaps of the electrode active materials.
H01M 4/485 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques d'oxydes ou d'hydroxydes mixtes pour insérer ou intercaler des métaux légers, p. ex. LiTi2O4 ou LiTi2OxFy
H01M 4/505 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de manganèse d'oxydes ou d'hydroxydes mixtes contenant du manganèse pour insérer ou intercaler des métaux légers, p. ex. LiMn2O4 ou LiMn2OxFy
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
Systems and methods are disclosed for electronic monitoring. A method of electronic monitoring comprises receiving a location of a participant, receiving data associated with the participant, and determining an alert level for the participant based on the data and the location of the participant.
The present disclosure relates to semiconductor heterojunctions incorporating porous semiconductor materials. In one aspect, the present disclosure provides a device comprising a p-type semiconductor material comprising a nanoporous semiconductor layer and a nonporous semiconductor layer that form a heterojunction; and a flexible substrate comprising one or more of polymers on which the p-type semiconductor material is distributed such that the flexible substrate is in contact with the nonporous semiconductor layer.
Embodiments are directed to a series of novel small molecule activators of NRF2 dependent gene expression that are evaluated in an effort to develop therapeutic methods against diseases with deregulated KEAP1-NRF2 signaling.
The instant disclosure provides reagent compounds, and antibody and oligonucleotide reagents, for use in a variety of assays, including immunoassays and nucleic acid hybridizations. The reagent compounds comprise a bridging antigen or bridging oligonucleotide and a latent crosslinker moiety, such as a tyramide moiety. The bridging antigens are recognizable by the antibody of a corresponding antibody reagent with high affinity, and the bridging oligonucleotides are complementary to the oligonucleotide of a corresponding oligonucleotide reagent. The antibody reagents and oligonucleotide reagents also comprise a crosslinker activation agent, such as a peroxidase enzyme. Reaction of the reagent compounds with the crosslinker activation agent results in the amplification of signal in assays for target cellular markers, including cellular antigens and nucleic acids. Also provided are detectable antibodies specific for the bridging antigens, kits comprising the reagent compounds and antibody and oligonucleotide reagents, methods of signal amplification using the compounds and reagents of the disclosure, methods of preparation of the compounds and reagents, and compositions comprising the compounds and reagents.
G01N 33/547 - Résine synthétique avec un antigène ou un anticorps liés au support par l'intermédiaire d'un agent de pontage
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
C12N 9/08 - Oxydoréductases (1.), p. ex. luciférase agissant sur le peroxyde d'hydrogène comme accepteur (1.11)
C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
C12Q 1/6804 - Analyse d’acides nucléiques utilisant des immunogènes
G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
G01N 33/535 - Production de composés immunochimiques marqués avec un marqueur enzymatique
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
UNIVERSITE DE MONTPELLIER (France)
INSTITUT REGIONAL DU CANCER DE MONTPELLIER (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
Inventeur(s)
Pan, Tao
Zhang, Wen
Abrégé
In general, the current disclosure relates to pre-queuosine1 (preQ1) affecting mammalian cellular function, including affecting proliferation of the mammalian cell. Aspects herein further show that preQ1 can affect tRNA abundance.
C12P 17/16 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle contenant plusieurs hétérocycles
95.
THIN SULFIDE-BASED SOLID-STATE ELECTROLYTES VIA SPRAY DEPOSITION
A solid electrolyte for solid-state batteries includes a lithium argyrodite film of formula of LinPxSyXz, where X is F, Cl, Br, I, or a mixture of two or more thereof, and where n is 1 to 10, x is 1 to 3, y is 3 to 8, and z is 1 to 3. The lithium argyrodite exhibits a polyamorphous microstructure and may have a thickness of about 1 μm to about 50 μm. The solid electrolyte is formed using spray decomposition deposition.
H01M 10/0585 - Structure ou fabrication d'accumulateurs ayant uniquement des éléments de structure plats, c.-à-d. des électrodes positives plates, des électrodes négatives plates et des séparateurs plats
96.
DYSFUNCTIONAL ANTIGEN-SPECIFIC CD8+ T CELLS IN THE TUMOR MICROENVIRONMENT
Provided herein are compositions and methods for detecting and/or targeting dysfunctional tumor antigen-specific CD8+ T cells in the tumor microenvironment for diagnostic, therapeutic and/or research applications. In particular, dysfunctional tumor antigen-specific CD8+ T cells are detected and/or targeted via their expression of cell surface receptors described herein, such as 4-1BB,LAG-3, or additional markers that correlate with 4-1BB and LAG-3 expression, such as markers differentially expressed on the surface of the T cells.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
97.
NANOSCALE METAL-ORGANIC FRAMEWORKS WITH X-RAY TRIGGERABLE PRODRUGS FOR COMBINATION RADIOTHERAPY, CHEMOTHERAPY, AND IMMUNOTHERAPY
A metal-organic framework (nMOF) including an X-ray sensitive prodrug is described. For instance, the MOF can include metal-containing secondary building units (SBU) that are linked together via organic bridging ligands where the SBU includes a metal cation that can absorb X-rays and where at least one organic bridging ligand is substituted by a monovalent moiety derived from a therapeutic agent, such as a chemotherapy and/or immunotherapy agent, via a group that includes a bond capable of radical-promoted bond cleavage. Methods of using the MOF to treat diseases, such as cancer, are also described. The methods can include the combination of radiotherapy or radiotherapy-radiodynamic therapy with chemotherapy or immunotherapy.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
This disclosure relates to methods for determining sodium concentration in biological samples. More particularly, this disclosure relates to methods capable of determining Na+ concentration using nucleic acid complexes.
G01N 33/84 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des composés inorganiques ou le pH
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
Provided herein are antibodies that bind α-Butyrophilin2A1 (BTN2A1), and diagnostic, therapeutic and research methods of use thereof. In particular, BTN2A1 antibodies are provided with substantially no cross-reactivity with α-Butyrophilin3A1 (BTN3A1), and in certain embodiments exhibiting BTN2A1 antagonism and/or inhibition of Vγ9Vδ2 T-cell activation.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
